# The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm

Study · id `cardio:ct-nct01674686` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01674686](<https://clinicaltrials.gov/study/NCT01674686>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT01674686

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT01674686. Randomized; single masking; primary purpose treatment. Start 2012-08-01 (actual); primary completion 2018-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT01674686, source copy `cardio:ctgov-nct01674686-2018-02-09`, retrieved 2026-11-18)
- Started: 2012-08-01 (actual) (ClinicalTrials.gov record NCT01674686, source copy `cardio:ctgov-nct01674686-2018-02-09`, retrieved 2026-11-18)
- Primary completion: 2018-12-31 (anticipated) (ClinicalTrials.gov record NCT01674686, source copy `cardio:ctgov-nct01674686-2018-02-09`, retrieved 2026-11-18)
- Completion: 2018-12-31 (anticipated) (ClinicalTrials.gov record NCT01674686, source copy `cardio:ctgov-nct01674686-2018-02-09`, retrieved 2026-11-18)
- Countries: South Korea (ClinicalTrials.gov record NCT01674686, source copy `cardio:ctgov-nct01674686-2018-02-09`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01674686-2018-02-09`, retrieved 2026-11-18)

## The registry's words

- Brief title: The Effect of Sarpogrelate and High Dose Statin on the Reduction of Coronary Spasm
- Condition: Variant Angina
- Intervention (Drug): Sarpogrelate
- Intervention (Drug): Atorvastatin
- Lead sponsor: Samsung Medical Center
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Microvascular and vasospastic angina (`cardio:microvascular-and-vasospastic-angina`)
- Registry intervention name matches this record: Atorvastatin (`cardio:atorvastatin`)
- Registry lists this organization as the lead sponsor: Samsung Medical Center (`cardio:org-samsung-medical-center`)

## Provenance

Content hash: 9dd7202f6fdb0be1d11d996a2ca3ac71d8bdf4e071fe59691ae0682b3b973ad2
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
